Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SEN. KENNEDY SEEKS DRUG COMPANY DETAIL FORCE SIZES

Executive Summary

SEN. KENNEDY SEEKS DRUG COMPANY DETAIL FORCE SIZES as part of the continuing preparation for threatened Senate Labor & Human Resources Committee hearings this summer on pharmaceutical promotional promotional and pricing practices. In June letters and telephone calls, the Massachusetts Democrat's committee staff has canvassed the drug industry for information on the size of detail forces in two benchmark years, 1985 and 1990. That type of specific inquiry is the kind that could lead to an instant chart or comparison to spice up an investigation nearing completion. Detail force sizes have been growing so rapidly and steadily during the 1980s that some management consultants are questioning the value of such large investments (See story, p. 16) The committee's chief investigator, Walter Sheridan, continues to head the pharmaceutical inquiry. Sheridan, who conducted the Kennedy investigations into pharmaceutical promotions in the 1970s, is being aided in the current effort by Mark Childress, a counsel to the committee. Kennedy also recently asked FDA for information on 20 prescription drugs. The committee requested NDA approval letters, official labeling and any documents pertaining to the advertising of the products. The FDA request sends a different type of signal on the status of the investigation. The broad inquiry indicates a continuing fishing trip for information. The Kennedy investigatory staff developed a reputation in the 1970's for carefully masking the thrust of hearings until the last moment. PMA has begun to prepare for potential hearings by reviewing the aggregate data on promotional activities already sent to Kennedy. The association reportedly held a meeting during the week of June 11-15 to review marketing practices with a representative group of senior marketing execs.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS017633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel